Avalo Therapeutics, Inc. (AVTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Avalo Therapeutics reported revenue of $59,000, down 86.6% from $441,000 the year before. Net income was -$78.3M (a -132642.4% net margin), or -$5.84 per diluted share. Gross margin was -123601.7% and operating margin was -123601.7%. Operating activities generated -$51.5M of cash, leaving -$51.5M of free cash flow. At fiscal year end, Avalo Therapeutics held $116.5M in total assets against $33.4M in total liabilities, including $15.9M of cash and equivalents.
Open the full interactive Avalo Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Avalo Therapeutics Key Stats
| Share Price | $12.01 |
|---|---|
| Market Cap | $523.7M |
| Revenue YoY Growth | -86.6% |
| 52-Week Range | $12.01 – $22.87 |
| Shares Outstanding | 43.6 million (basic, 2026 Q2) |
Avalo Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $6.7M | $5.4M | $18.1M | $1.9M | $441,000 | $59,000 |
| Cost of Goods Sold | $300,199 | $1.5M | $3.4M | $1.3M | $69.0M | $73.0M |
| Gross Profit | $6.4M | $3.9M | $14.6M | $640,000 | -$68.5M | -$72.9M |
| Operating Income | -$72.8M | -$82.1M | -$37.4M | -$27.4M | -$68.5M | -$72.9M |
| Pre-Tax Income | -$66.3M | -$84.6M | -$41.6M | -$31.5M | -$35.0M | -$78.1M |
| Income Tax | -$2.8M | -$196,000 | $28,000 | $14,000 | $114,000 | $165,000 |
| Net Income | -$63.5M | -$84.4M | -$41.7M | -$31.5M | -$35.1M | -$78.3M |
| Diluted EPS | -$2742.29 | -$2390.40 | -$1063.20 | -$114.00 | -$20.91 | -$5.84 |
Avalo Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $59,000 | $0 | $0 |
| Net Income | -$30.6M | -$13.7M | -$19.6M | -$36.4M |
| Diluted EPS | -$2.19 | -$1.02 | -$0.98 | -$0.83 |
Avalo Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.9M | $54.6M | $13.2M | $7.4M | $134.5M | $15.9M |
| Current Assets | $26.0M | $61.8M | $16.4M | $8.4M | $138.9M | $105.3M |
| Total Assets | $43.8M | $80.2M | $33.4M | $21.0M | $150.7M | $116.5M |
| Current Liabilities | $15.2M | $19.9M | $22.1M | $4.6M | $7.0M | $12.9M |
| Total Long-Term Debt | — | $32.8M | $19.4M | — | — | — |
| Total Liabilities | $19.2M | $57.1M | $44.3M | $13.7M | $17.7M | $33.4M |
| Shareholders' Equity | $24.6M | $23.1M | -$10.9M | $7.3M | $133.0M | $83.0M |
Avalo Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$40.5M | -$70.9M | -$26.8M | -$30.7M | -$49.1M | -$51.5M |
| Cash From Investing | $11.1M | -$113,000 | -$95,000 | -$133,000 | $356,000 | -$81.7M |
| Cash From Financing | $44.8M | $106.8M | -$14.7M | $25.0M | $175.8M | $14.6M |
| Free Cash Flow | -$40.6M | -$71.0M | -$26.9M | -$30.7M | -$49.1M | -$51.5M |
Figures from Avalo Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Avalo Therapeutics financials page for every line item.
Avalo Therapeutics Company Profile
| Ticker | AVTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Wayne, Pennsylvania |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001534120 |
Frequently Asked Questions
What was Avalo Therapeutics' revenue in fiscal 2025?
Avalo Therapeutics (AVTX) reported revenue of $59,000 for fiscal 2025.
What is Avalo Therapeutics' annual revenue history?
Avalo Therapeutics' annual revenue by fiscal year: 2020: $6.7M; 2021: $5.4M; 2022: $18.1M; 2023: $1.9M; 2024: $441,000; 2025: $59,000.
What was Avalo Therapeutics' net income in fiscal 2025?
Avalo Therapeutics reported net income of -$78.3M for fiscal 2025.
What was Avalo Therapeutics' earnings per share (EPS) in fiscal 2025?
Avalo Therapeutics' diluted EPS was -$5.84 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Avalo Therapeutics generate in fiscal 2025?
Avalo Therapeutics generated -$51.5M of free cash flow in fiscal 2025.
What was Avalo Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Avalo Therapeutics reported revenue of $0.
How many shares of Avalo Therapeutics are outstanding?
Avalo Therapeutics reported a weighted average of 43.6 million basic shares outstanding in 2026 Q2.
What is Avalo Therapeutics' market cap?
Based on its latest closing price, Avalo Therapeutics (AVTX) has a market capitalization of about $523.7M.
When does Avalo Therapeutics' fiscal year end?
Avalo Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Avalo Therapeutics headquartered?
Avalo Therapeutics lists its business address in Wayne, Pennsylvania in its SEC filings.